Option Care Health, Inc.

Option Care Health, Inc. (OPCH) Market Cap

Option Care Health, Inc. has a market capitalization of $4.51B.

Financials based on reported quarter end 2025-12-31

Price: $28.82

0.49 (1.73%)

Market Cap: 4.51B

NASDAQ · time unavailable

CEO: John C. Rademacher

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 1996-08-15

Website: https://www.optioncarehealth.com

Option Care Health, Inc. (OPCH) - Company Information

Market Cap: 4.51B · Sector: Healthcare

Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as amyotrophic lateral sclerosis and duchenne muscular dystrophy; infusion therapies for bleeding disorders; therapies that women need to survive and thrive through high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.

Analyst Sentiment

86%
Strong Buy

Based on 12 ratings

Analyst 1Y Forecast: $38.13

Average target (based on 3 sources)

Consensus Price Target

Low

$36

Median

$39

High

$42

Average

$39

Potential Upside: 34.2%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 OPTION CARE HEALTH INC (OPCH) — Investment Overview

🧩 Business Model Overview

Option Care Health Inc (OPCH) is the largest independent provider of home and alternate site infusion services in the United States. The company delivers comprehensive, high-touch clinical care to patients transitioning from hospital to home or outpatient infusion centers. Option Care Health’s business model bridges the gap between acute hospital care and patients’ homes by collaborating with payors, biopharmaceutical companies, and physicians to offer cost-effective, evidence-driven infusion therapies. Core therapy areas include nutrition support, anti-infectives, immunoglobulin, chronic inflammatory disorders, and oncology. With a national network of pharmacies and infusion suites, alongside in-home nursing capabilities, OPCH delivers services across numerous states and metropolitan areas, servicing a wide spectrum of patient populations who require complex medication regimens outside traditional inpatient settings.

💰 Revenue Streams & Monetisation Model

Option Care Health’s revenues are predominately derived from the provision of infusion therapy services, billed to commercial insurers, government-sponsored programs (including Medicare and Medicaid), and individual patients. Reimbursement models are driven by negotiated payer contracts and fee-for-service arrangements. The company also earns revenue through the distribution and compounding of pharmaceuticals and ancillary supplies furnished during therapy administration. Importantly, revenue streams are closely tied to the complexity and acuity of therapies provided, with oncology, immunoglobulin, and specialty chronic care infusions generally generating higher margins due to clinical intensity. Relationships with biopharma manufacturers act as another source of revenue, particularly in supporting the commercialization of novel infused drugs and biologics that require complex patient management and distribution logistics.

🧠 Competitive Advantages & Market Positioning

OPCH stands out within the alternate site infusion industry due to its national scale, broad clinical capabilities, and established health system integration. The company’s competitive strengths include: - **Extensive Infrastructure**: A coast-to-coast network of infusion pharmacies and suites strengthens the ability to serve geographically diverse payor and patient bases, giving OPCH scale and logistical advantages. - **Clinically Integrated Model**: Strong physician, payor, and health system relationships facilitate seamless referrals and transitions of care, reducing patient leakage and improving outcomes. - **Therapeutic Breadth**: The company’s expertise across varied and high-complexity disease states positions it as a preferred partner for both healthcare systems and the pharmaceutical industry. - **Robust Compliance Systems**: With deep experience navigating the intricacies of reimbursement, pharmacy regulation, and accreditation, OPCH mitigates operational risk relative to smaller or less-specialized competitors. - **Data & Outcomes Focus**: Investments in data analytics and care coordination enhance the company’s value proposition to payors seeking cost containment and quality assurance. OPCH competes with both large health system-affiliated providers and regional/homegrown infusion companies. Its market-leading footprint and scalable operations make it a preferred national partner for managed care organizations and drug manufacturers.

🚀 Multi-Year Growth Drivers

Multiple secular and company-specific tailwinds underpin OPCH’s long-term growth trajectory: - **Shift to Home-Based Care**: Payers, providers, and patients are increasingly migrating chronic and acute therapy administration from hospitals to the home due to lower costs and improved patient satisfaction, significantly expanding OPCH’s addressable market. - **Increasing Chronic Disease Burden**: Rising incidence and improved diagnosis of chronic autoimmune, inflammatory, and oncology indications increase the demand for complex infused therapies. - **Specialty Drug Innovation**: Continued pipeline advancement in specialty pharmaceuticals, including biologics and gene therapies, increases the volume and acuity of home-based therapies. - **Pharma Partnerships**: Collaboration opportunities with drug developers expand as the complexities of therapy management and patient support intensify, positioning OPCH as a preferred commercialization partner. - **Value-Based Care Alignment**: Healthcare cost containment and quality initiatives favor providers with track records of compliance, outcomes, and scale, reinforcing OPCH’s market positioning.

⚠ Risk Factors to Monitor

Despite its favorable outlook, OPCH’s business faces several key risks: - **Reimbursement Pressures**: Changes in reimbursement methodologies, particularly from government programs, can compress margins and profitability. - **Regulatory Scrutiny**: Infusion pharmacy is highly regulated, and changes in compounding laws, licensing, or accreditation requirements may raise compliance costs or restrict certain therapies. - **Competitive Threats**: Large health systems expanding their in-house capabilities, pharmacy benefit managers, and horizontal M&A within the space could intensify competition or pressure pricing. - **Operational Complexity**: The need to manage clinical quality, medication safety, and logistics at scale exposes the company to operational risks, including drug shortages and supply chain disruptions. - **Technology and Cybersecurity**: Growing reliance on digital health tools and patient data requires ongoing investment in cybersecurity and health IT infrastructure. - **Key Customer Concentration**: Dependence on major payors or health system relationships could create concentration risk if contracts are lost or not renewed.

📊 Valuation & Market View

Option Care Health typically trades at a valuation multiple that reflects both its predictable, recurring revenue mix and growth prospects. Key valuation considerations include: - **Recurring Revenue Base**: Stable, long-term contracts with payors support dependable cash flow generation, which is often valued at a premium versus more cyclical healthcare service providers. - **Margin Profile**: Margin expansion potential is underpinned by operating leverage, service mix improvements, and therapeutic innovation. - **Acquisition Platform**: As a consolidator in a fragmented market, Option Care Health is frequently analyzed for accretive M&A potential, which can drive multiple expansion over time. - **Peer Comparison**: Valuation is typically benchmarked against specialty pharmacy providers, home healthcare leaders, and alternate site therapy peers, with consideration for scale, growth, and clinical complexity. - **Balance Sheet & Capital Allocation**: Prudent leverage and the ability to deploy capital toward organic growth or inorganic opportunities support the long-term investment case. Market consensus recognizes OPCH as a leader in a defensive, expanding sector, emphasizing its growth visibility, competitive moat, and resilient operating model.

🔍 Investment Takeaway

Option Care Health Inc represents a unique platform within U.S. healthcare, positioned at the intersection of specialty pharmacy, home-based care, and chronic disease management. The company’s national scale, clinical intensity, and integration with key stakeholders provide sustainable competitive advantages in an expanding market. Structural industry shifts toward home infusion, combined with pharmaceutical innovation and alignment with value-based care imperatives, are likely to sustain multi-year growth. Investors must monitor reimbursement dynamics, regulatory evolution, and competitive activity, but OPCH’s diversified revenue base, proven execution, and consolidation opportunities underpin its appeal as a core healthcare holding with both defensive and growth characteristics.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"Headline (latest quarter, 2025-12-31): Revenue $1.465B and net income $58.5M, EPS $0.37. QoQ Revenue grew ~+2.1% (from $1.435B) and net income rose ~+12.8% (from $51.8M). Across the 4-quarter window, revenue increased from $1.333B (2025-03-31) to $1.465B (2025-12-31), while net income rose from $46.7M to $58.5M; net income margin improved to ~4.0% (vs ~3.6% in the prior quarter), indicating profitability expansion. Cash flow was mixed. Operating cash flow declined to $35.9M from $139.4M in the prior quarter, and free cash flow fell to $17.4M (vs $157.9M). There is no dividend paid. Balance sheet resilience looks mixed: total assets were slightly down QoQ (~$3.456B vs $3.480B) and equity declined (~$1.326B vs $1.359B), but net debt swung to net cash (netDebt -$232.6M) from meaningful net debt in prior quarters—an important liquidity positive. Shareholder returns appear negative: the stock is down ~-11.0% over 1Y with no dividends and no buyback data provided, so total shareholder returns are likely trailing. Valuation sentiment is supportive: consensus price target is $38.14 and median $37 vs current $28.34 (~+30% upside). Note: YoY comparisons for Revenue and Net Income were not possible because prior-year same-quarter data was not provided."

Revenue Growth

Neutral

QoQ revenue improved to $1.465B (+~2.1% vs 2025-09-30). Over the 4-quarter period, revenue rose from $1.333B to $1.465B. YoY growth rates were not calculable because prior-year same-quarter figures were not provided.

Profitability

Positive

Net income rose to $58.5M (+~12.8% QoQ) and net margin improved to ~4.0% from ~3.6% in the prior quarter, suggesting profitability is expanding. EPS increased from $0.32 to $0.37 QoQ.

Cash Flow Quality

Caution

Free cash flow weakened materially to $17.4M from $157.9M QoQ, despite positive FCF. Dividend payments are $0, and buyback/FCF allocation details were not provided.

Leverage & Balance Sheet

Neutral

Assets were slightly down QoQ (~$3.456B vs $3.480B) and equity declined (~$1.326B vs $1.359B), but the key offset is a strong liquidity swing: net debt moved to net cash (-$232.6M) from positive net debt in prior quarters.

Shareholder Returns

Caution

1Y price performance is negative (-10.99%). No dividends are paid, and buybacks are not evidenced in the provided data, implying total shareholder returns likely lag.

Analyst Sentiment & Valuation

Positive

Valuation/expectations look constructive: median target $37 and consensus $38.14 vs current $28.34 (~+30% upside). P/E improved over the 4-quarter period (from ~30.9 to ~21.5), supporting sentiment.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management’s tone is confident and execution-focused, repeatedly emphasizing that 2026 guidance is reaffirmed “no changes” despite heavy Stelara-related headwinds. The hard numbers confirm that confidence is partly accounting-driven: 2026 revenue guidance includes a 400 bps growth headwind from Stelara IRA/biosimilar conversion, and EBITDA includes a $25M–$35M gross profit headwind (evenly through the year). In the Q&A, the analyst pressure is less about strategic direction and more about quantification and operational constraints: Stelara’s Q4 impact was validated as “patterned exactly,” roughly ~$20M impacting gross profit and described as >100 bps impact. On operations, management disclosed the key limiting factor for advanced practitioner clinic scale—state corporate practice of medicine and payer credentialing—declining to provide a numeric 2026 site-opening target. Net: bullish on acute demand and payer/pharma traction, but cautious on mix and conversion headwinds that will keep profitability growth below “normalized” levels until Stelara effects fully burn off.

AI IconGrowth Catalysts

  • Increased payer-driven site-of-care transitions (home, infusion suites, infusion clinics) to reduce total cost of care
  • Stelara biosimilar adoption integration running in-line with expectations (no guidance change)
  • Expansion of ambulatory infusion clinic footprint: 25+ centers offering advanced practitioner capabilities
  • Intramed Plus integration momentum: infusion clinic visits grew >25% in Q4 vs prior year
  • Automation/AI enabling scalability: ~40% of claims processed without human intervention

Business Development

  • Active site-of-care programs with largest national payers; added 5 new programs with regional health plans and 2 with nontraditional payers (incremental traction expected to grow in 2026)
  • Pharma partnerships with enhanced service and data insight programs; operate 20+ enhanced programs serving pharma manufacturers (pipeline of new programs expected to launch in 2026+)

AI IconFinancial Highlights

  • FY2025 net revenue: $5.6B (+13% YoY)
  • FY2025 gross profit dollars: +7.4%; SG&A % of sales: 12.1% (down 50 bps YoY)
  • FY2025 adjusted EBITDA: $471M (+6% YoY); EBITDA margin: 8.3%
  • FY2025 adjusted diluted EPS: $1.72 (+9% YoY)
  • FY2025 cash flow from operations: $258M; net debt leverage ratio: 2.0x
  • FY2025 headwind from Stelara biosimilars: 160 bps revenue headwind due to patient transitions within chronic portfolio
  • Q4 Stelara impact quantified by analyst Q&A: headwind ~ $70M; assumes ~$20M gross profit impact in Q4 and described as >100 bps gross profit impact
  • 2026 guidance reiterated (no changes vs January): revenue $5.8B–$6.0B (4% growth at midpoint) with 400 bps revenue growth headwind from Stelara IRA + Stelara biosimilars conversion
  • 2026 adjusted EBITDA guidance: $480M–$505M; includes $25M–$35M gross profit headwind related to Stelara/biosimilars (evenly realized over the year)
  • 2026 adjusted diluted EPS: $1.82–$1.92; 2026 operating cash flow: >$340M
  • 2026 modeling assumptions: net interest expense $50M–$55M; tax rate 26%–28%; Q1 share count ~159M

AI IconCapital Funding

  • 2025 share repurchases: >$300M
  • Board expanded share repurchase authorization by $500M (announced early January)
  • No new debt level disclosed in provided transcript (net debt leverage ratio remained 2.0x at FY2025 close)

AI IconStrategy & Ops

  • Automation: deployed AI to automate key patient administration functions (invoice processing, cash posting); ~40% of claims processed without human intervention
  • Capacity/efficiency focus: added >80 infusion chairs in 2025; maximize utilization within existing infrastructure
  • Nursing efficiency: management referenced ~20% improvement over time; further expected benefit from using infusion suites/clinics (also noted >34% of nursing visits in Q4 occurred in suites/clinics)
  • Advanced practitioner clinic build: growth via (1) greenfield builds and (2) conversion of existing sites requiring licensure + modest refurb; exact 2026 site-opening targets not provided

AI IconMarket Outlook

  • Management reiterated 2026 guidance without modification
  • 2026 acute growth expectation: industry low-single digit; OPCH expecting mid-single digit
  • 2026 chronic growth expectation: high single-digit to low double-digit (with Stelara/biosimilar headwinds on YoY baseline)
  • Q1 characterized as a seasonal/operational busy period (benefit verification, reauthorization, prior authorization); management expects a “shake out” after Q1

AI IconRisks & Headwinds

  • Stelara biosimilars and Stelara IRA conversions: FY2025 160 bps revenue headwind; 2026 400 bps revenue growth headwind; Q4 gross profit headwind patterning to expectations
  • Mix pressure in 2026: chronic expected to grow faster than acute, creating gross margin pressure as a % (mitigated by performance/execution)
  • Working capital drag in FY2025: increased working capital for certain limited distribution therapies beyond estimate due to clinical/operational investment needs; management targeting inventory timing as mitigation and described cash conversion improving over time
  • Regulatory/credentialing constraint on advanced practitioner clinic expansion: pace limited by state-level corporate practice of medicine rules and payer credentialing; also requires refurb/licensure and balance of pharmacy vs advanced practitioner patient routing

Sentiment: MIXED

Note: This summary was synthesized by AI from the OPCH Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (OPCH)

© 2026 Stock Market Info — Option Care Health, Inc. (OPCH) Financial Profile